P
Peter P. Rainer
Researcher at Medical University of Graz
Publications - 91
Citations - 2073
Peter P. Rainer is an academic researcher from Medical University of Graz. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 22, co-authored 69 publications receiving 1348 citations. Previous affiliations of Peter P. Rainer include Medical University of Vienna & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease
Dong I. Lee,Guangshuo Zhu,Takashi Sasaki,Gun Sik Cho,Nazha Hamdani,Ronald J. Holewinski,Su Hyun Jo,Thomas Danner,Manling Zhang,Peter P. Rainer,Djahida Bedja,Jonathan A. Kirk,Mark J. Ranek,Wolfgang R. Dostmann,Chulan Kwon,Kenneth B. Margulies,Jennifer E. Van Eyk,Walter Paulus,Eiki Takimoto,David A. Kass +19 more
TL;DR: It is shown that cGMP-selective PDE9A is expressed in the mammalian heart, including humans, and is upregulated by hypertrophy and cardiac failure, and its role in stress-induced heart disease suggests potential as a therapeutic target.
Journal ArticleDOI
Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy
Kinya Seo,Peter P. Rainer,Peter P. Rainer,Virginia S. Hahn,Dong Ik Lee,Su Hyun Jo,Su Hyun Jo,Asger Andersen,Ting Liu,Xiaoping Xu,Robert N. Willette,John J. Lepore,Joseph P. Marino,Lutz Birnbaumer,Christine G. Schnackenberg,David A. Kass +15 more
TL;DR: Although gene deletion of TRPC3 or TRPC6 alone did not protect against hypertrophy or dysfunction from pressure overload, combined deletion was protective, supporting the value of dual inhibition and further development of this pharmaceutical class may yield a useful therapeutic agent for heart disease management.
Journal ArticleDOI
Elevated Cardiac Troponin T in Patients With Skeletal Myopathies
Johannes Schmid,Laura Liesinger,Ruth Birner-Gruenberger,Tatjana Stojakovic,Hubert Scharnagl,Benjamin Dieplinger,Martin Asslaber,Roman Radl,Meinrad Beer,Malgorzata Polacin,Johannes Mair,Dieter H. Szolar,Andrea Berghold,Stefan Quasthoff,Josepha S. Binder,Peter P. Rainer +15 more
TL;DR: Measured cTnT concentrations were chronically elevated in the majority of patients with skeletal myopathies, whereascTnI elevation was rare, and data indicate that cross-reaction of the cTNT immunoassay with skeletal muscle troponin isoforms was the likely cause.
Journal ArticleDOI
Empagliflozin protects heart from inflammation and energy depletion via AMPK activation.
Chintan N. Koyani,Ioanna Plastira,Harald Sourij,Seth Hallström,Albrecht Schmidt,Peter P. Rainer,Heiko Bugger,Saša Frank,Ernst Malle,Dirk von Lewinski +9 more
TL;DR: The authors' data identify a novel cardio protective mechanism of SGLT2 inhibitor, empagliflozin, suggesting that AMPK activation-mediated energy repletion and reduced inflammation contribute to the observed cardiovascular benefits of the drug in HF.
Journal ArticleDOI
Hyperactive Adverse Mechanical Stress Responses in Dystrophic Heart Are Coupled to Transient Receptor Potential Canonical 6 and Blocked by cGMP–Protein Kinase G Modulation
Kinya Seo,Peter P. Rainer,Dong Ik Lee,Scarlett Hao,Djahida Bedja,Lutz Birnbaumer,Oscar H. Cingolani,David A. Kass +7 more
TL;DR: In this paper, the role of transient receptor potential canonical channels (TRPC3 and TRPC6) and their modulation by protein kinase G in controlling cardiac systolic mechano-sensing was investigated in an experimental model of Duchenne muscular dystrophy.